BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34975899)

  • 1. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Ruder J; Rex J; Obahor S; Docampo MJ; Müller AMS; Schanz U; Jelcic I; Martin R
    Front Immunol; 2021; 12():794077. PubMed ID: 34975899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.
    Darlington PJ; Stopnicki B; Touil T; Doucet JS; Fawaz L; Roberts ME; Boivin MN; Arbour N; Freedman MS; Atkins HL; Bar-Or A
    Front Immunol; 2018; 9():834. PubMed ID: 29867923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.
    Cencioni MT; Genchi A; Brittain G; de Silva TI; Sharrack B; Snowden JA; Alexander T; Greco R; Muraro PA
    Front Immunol; 2021; 12():813957. PubMed ID: 35178046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
    Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A
    J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
    Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
    Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
    Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
    Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation.
    Arruda LCM; de Azevedo JTC; de Oliveira GLV; Scortegagna GT; Rodrigues ES; Palma PVB; Brum DG; Guerreiro CT; Marques VD; Barreira AA; Covas DT; Simões BP; Voltarelli JC; Oliveira MC; Malmegrim KCR
    Clin Immunol; 2016 Aug; 169():47-57. PubMed ID: 27318116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
    Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
    Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
    Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
    Front Immunol; 2020; 11():559. PubMed ID: 32328061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
    Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
    Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
    Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
    Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.
    Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E
    Front Immunol; 2021; 12():625165. PubMed ID: 33777007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation.
    Servaas NH; Spierings J; Pandit A; van Laar JM
    Clin Exp Immunol; 2020 Jul; 201(1):34-39. PubMed ID: 31990046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression.
    Zahran AM; Abdel-Rahim MH; Elsayh KI; Hassanien MM; Mahran SA; Hetta HF
    Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):161-169. PubMed ID: 30944972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
    Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
    J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells.
    Vukicevic M; Chalandon Y; Helg C; Matthes T; Dantin C; Huard B; Chizzolini C; Passweg J; Roosnek E
    Eur J Immunol; 2010 Nov; 40(11):3246-54. PubMed ID: 20957748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.